Neumora Therapeutics to Participate in Upcoming Conferences in November
Rhea-AI Summary
Neumora Therapeutics (Nasdaq: NMRA) will participate in two investor conferences in November 2025. Management will take part in fireside chats at the Guggenheim 2nd Annual Healthcare Innovation Conference on Monday, November 10, 2025 at 2:30 p.m. ET in Boston and at the Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025 at 2:00 p.m. ET in New York.
A live webcast of both events will be available on the company's events and presentations webpage at www.neumoratx.com, with replays archived for up to 30 days after the events.
Positive
- None.
Negative
- None.
News Market Reaction 8 Alerts
On the day this news was published, NMRA declined 0.33%, reflecting a mild negative market reaction. Argus tracked a trough of -2.5% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $1M from the company's valuation, bringing the market cap to $452M at that time.
Data tracked by StockTitan Argus on the day of publication.
WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will participate in two investor conferences in November.
- Guggenheim 2nd Annual Healthcare Innovation Conference: Members of management will participate in a fireside chat on Monday, November 10, 2025, at 2:30 p.m. ET in Boston, MA.
- Stifel 2025 Healthcare Conference: Members of management will participate in a fireside chat on Wednesday, November 12, 2025, at 2:00 p.m. ET in New York, NY.
A live webcast of the events will be available on the events and presentations section of the Company’s website at www.neumoratx.com. A replay of the webcasts will be available following the completion of the events and will be archived for up to 30 days.
About Neumora
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the greatest medical challenges of our generation by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our therapeutic pipeline currently consists of seven programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases. Neumora’s mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients.
Neumora Contact:
Helen Rubinstein
617-402-5700
Helen.Rubinstein@neumoratx.com
FAQ
When will Neumora Therapeutics (NMRA) present at the Guggenheim Healthcare Innovation Conference?
When is Neumora Therapeutics (NMRA) scheduled to speak at the Stifel 2025 Healthcare Conference?
Where can investors watch the Neumora (NMRA) conference webcasts live?
Will Neumora (NMRA) provide replays of the November 2025 conference presentations?
What will Neumora (NMRA) management do at the November 2025 conferences?
Are the Neumora (NMRA) conference sessions accessible to remote investors on specific dates?
